Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
The BeST Trial: Bevacizumab, Sorafenib, and Temsirolimus in Advanced Renal Cell Carcinoma
NCT00378703Phase 2Completed
- Sponsor
- National Cancer Institute
- Start
- Sep 2007
- Primary completion
- Feb 2014
- Modality
- Small Molecules, Monoclonal Antibodies
- Countries
- 2
01
Overview
A Phase 2 trial of bevacizumab, sorafenib, temsirolimus in renal cell carcinoma (RCC), sponsored by National Cancer Institute. Started Sep 2007; status: completed.
02
Drugs
bevacizumabsorafenibtemsirolimus
03
Conditions
renal cell carcinoma (RCC)
Beyond the preview
Go deeper on NCT00378703.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00378703.